Efficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab

Jose A. Carrillo, Frank P.K. Hsu, Johnny Delashaw, Daniela Bota

DOI: https://doi.org/10.7175/rhc.v5i1.668

Abstract

Despite recent advances in the treatment of malignant gliomas (World Health Organization grade III and grade IV tumors- Glioblastoma Multiforme, Anaplastic Astrocytoma and Anaplastic Oligodendroglioma), the overall prognosis remains poor. Tumor recurrence in malignant glioma is inevitable, and associated with reduced overall survival (OS). Bevacizumab is approved for use in progressive GBM as a second line treatment, and is associated with improvements in progression free survival (PFS). However, all GBM patients eventually recur on bevacizumab therapy, with a very short OS after bevacizumab failure. No FDA-approved therapy is available for this clinical setting. Etoposide crosses the blood-brain barrier and has activity in recurrent malignant gliomas. The use of bevacizumab with etoposide in recurrent malignant gliomas in the setting of bevacizumab resistance is evaluated in this review. Bevacizumab and etoposide combined therapy is associated with radiographic response and effectiveness in selected patients.

Keywords

Bevacizumab; Etoposide; Malignant Gliomalioblastoma Multiforme, Malignant Glioma, GBM

Full Text

HTML PDF

References

  • CBTRUS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2008. In: Central Brain Tumor Registry of the United States. CBTRUS, 2012
  • Stupp R, Mason WP, van den Bent MJ, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009; 10: 459-466; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
  • Stupp R, van den Bent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 2005; 352: 987-996; http://dx.doi.org/10.1056/NEJMoa043330
  • Schmidt NO, Hagel C, Ergun S, et al. Levels of Vascular Endothelial Growth Factor, Hepatocyte Growth Factor/Scatter Factor and Basic Fibroblast Growth Factor in Human Gliomas and Their Relation to Angiogenesis. International Journal of Cancer 1999; 84: 10-8; http://dx.doi.org/10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.0.CO;2-L
  • Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 1997; 93: 109-17; http://dx.doi.org/10.1007/s004010050591
  • Samoto K, Ikezaki K, Ono M. Expression of Vascular Endothelial Growth Factor and Its Possible Relation with Neovascularization in Human Brain Tumors. Cancer Res 1995; 55: 1189-93
  • Lamszus K, Ulbricht U, Matschke J, et al. Levels of Soluble Vascular Endothelial Growth Factor (VEGF) Receptor 1 in Astrocytic Tumors and Its Relation to Malignancy, Vascularity, and VEGF-A. Clin Cancer Res 2003; 9: 1399-405
  • Zhou YH, Tan F, Hess KR, et al. The Expression of PAX6, PTEN, Vascular Endothelial Growth Factor, and Epidermal Growth Factor Receptor in Gliomas: Relationship to Tumor Grade and Survival. Clin Cancer Res 2003; 9: 3369-75
  • Rubenstein JL, Ozawa T, Zhang M, et al. Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption. Neoplasia 2000; 2: 306-14; http://dx.doi.org/10.1038/sj.neo.7900102
  • Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012; 118: 1302-12; http://dx.doi.org/10.1002/cncr.26381
  • Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611; http://dx.doi.org/10.1210/er.2003-0027
  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-9; http://dx.doi.org/10.1200/JCO.2007.12.2440
  • Friedman HS, Prados MD, Wen PY, et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-40; http://dx.doi.org/10.1200/JCO.2008.19.8721
  • Weller M, Cloughesy T, Perry JR, et al., Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol 2013; 15: 4-27; http://dx.doi.org/10.1093/neuonc/nos273
  • Kyritsis AP, Levin VA. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemother Pharmacol 2011; 67: 971-83; http://dx.doi.org/10.1007/s00280-011-1617-9
  • Reardon DA, Desjardins A, Peters KB, et al., Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011; 117: 5351-8; http://dx.doi.org/10.1002/cncr.26188
  • Reardon DA, Desjardins A, Peters K, et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011; 103: 371-9; http://dx.doi.org/10.1007/s11060-010-0403-6
  • Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-5; http://dx.doi.org/10.1200/JCO.2008.16.3055
  • Scott BJ, Quant EC, McNamara MB, et al. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 2010; 12: 603-7; http://dx.doi.org/10.1093/neuonc/nop073
  • Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011; 114: 1609-16; http://dx.doi.org/10.3171/2010.10.JNS101042
  • Clark AJ, Lamborn KR, Butowski NA, et al. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery 2012; 70: 361-70; http://dx.doi.org/10.1227/NEU.0b013e3182314f9d
  • Kiya K, Uozumi T, Ogasawara H, et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 1992; 29: 339-42; http://dx.doi.org/10.1007/BF00686001
  • Sevim H, Parkinson JF, McDonald KL. Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha? J Cancer Res Clin Oncol 2011; 137: 1705-12; http://dx.doi.org/10.1007/s00432-011-1046-5
  • Tirelli U, D’Incalci M, Canetta R, et al. Etoposide (VP-16-213) in Malignant Brain Tumors: A Phase II Study. Journal of Clinical Oncology 1984; 2: 432-7
  • Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996; 27: 149-55; http://dx.doi.org/10.1007/BF00177478
  • Korones DN, Benita-Weiss M, Coyle TE, et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 2003; 97: 1963-8; http://dx.doi.org/10.1002/cncr.11260
  • Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and Etoposide Chemotherapy Regimen for Recurrent Malignant Glioma: A Phase II Study. J Clin Oncol 1992; 10: 1074-7
  • Watanabe K, Kanaya H, Fujiyama Y, et al. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study. Acta Neurochir (Wien) 2002; 144: 1265-70; http://dx.doi.org/10.1007/s00701-002-1023-5
  • Franceschi E, Cavallo G, Scopece L, et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 2004; 91: 1038-44
  • Sanson M, Monjour A, Sahmoud T, et al. Treatment of Recurrent Malignant Supratentorial Gliomas with Ifosfamide, Carboplatin and Etoposide: a Phase II Study. Eur J Cancer 1996; 32: 2229-35; http://dx.doi.org/10.1016/S0959-8049(96)00299-7
  • Aoki T, Mizutani T, Nojima K, et al. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg 2010; 112: 50-6; http://dx.doi.org/10.3171/2009.5.JNS081738
  • Schäfer N, Tichy J, Thanendrarajan S, et al. Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Oncology 2011; 80: 330-2; http://dx.doi.org/10.1159/000330358
  • Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007; 9: 354-63; http://dx.doi.org/10.1215/15228517-2007-006
  • Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009; 101: 1986-94; http://dx.doi.org/10.1038/sj.bjc.6605412
  • Fu BD, Linskey ME, Bota DA. Bevacizumab and etoposide combination chemotherapy in patients with recurrent malignant gliomas who failed bevacizumab. Drugs and Therapy Studies 2012; 2: 26-8; http://dx.doi.org/10.4081/dts.2012.e6
  • Francesconi AB, Dupre S, Matos M, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 2010; 17: 970-4; http://dx.doi.org/10.1016/j.jocn.2009.12.009
  • Reardon DA, Vredenburgh JJ, Coan A, et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 2011; 105: 621-7; http://dx.doi.org/10.1007/s11060-011-0631-4
  • Hegi ME, Diserens AC, Gorlia T, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 2005; 352: 997-1003; http://dx.doi.org/10.1056/NEJMoa043331
  • Watanabe T, Katayama Y, Ogino A, et al. Preliminary Individualized Chemotherapy for Malignant Astrocytomas Based on O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Methylation Analysis. Neurol Med Chir 2006; 46: 387-4; http://dx.doi.org/10.2176/nmc.46.387
  • Clarke JL, Chang S. Pseudoprogression and Pseudoresponse: Challenges in Brain Tumor Imaging. Curr Neurol Neurosci Rep 2009; 9: 241-6; http://dx.doi.org/10.1007/s11910-009-0035-4
  • Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009; 22: 633-8; http://dx.doi.org/10.1097/WCO.0b013e328332363e
  • Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011; 32: 1978-85; http://dx.doi.org/10.3174/ajnr.A2397
  • Galanis E, Wu W, Cloughesy T, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol 2012; 13: e196-204; http://dx.doi.org/10.1016/S1470-2045(11)70406-5
  • Macdonald DR, Cascino TL, Schold SC Jr, et al. Response Criteria for Phase II Studies of Supratentorial Malignant Glioma. J Clin Oncol 1990; 8: 1277-80

Statistics

Abstract: 2120 views
HTML: 1180 views
PDF: 189 views

Refbacks

  • There are currently no refbacks.




© SEEd srl